At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- WAL0921 (drug), Placebo (drug)
- How long the study runs
- Study runs about 35 months (dates as stated)
- About the drug or intervention
- WAL0921 — drug: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions. · Placebo — drug: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a medicine called WAL0921 in adults with certain kidney diseases that affect the filters in the kidneys (glomerular kidney diseases). These include diabetic kidney disease and several other conditions. Not stated — ask the trial team for details on how the treatment works.
Who can take part
- Adults aged 18 to 75
- Diagnosis of one of these kidney diseases: diabetic nephropathy, primary focal segmental glomerulosclerosis (scarring of kidney filters), treatment-resistant minimal change disease, primary immunoglobulin A (IgA) nephropathy, or primary membranous nephropathy
- Kidney filtration rate (eGFR) of 30 or higher
Who may not be able to
- Currently pregnant or planning to become pregnant
- Previous organ transplant
- History of alcohol or substance use disorder
- Dialysis or sudden kidney injury within the last 6 months
- Any other condition that, in the doctor's judgement, would make taking part unsafe or prevent completing the study
What taking part involves
- • Taking the study medicine WAL0921 — details of how it is given are not stated — ask the trial team
Time commitment: Number of visits and study length are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 75 Years
- Who
- All
- Number of participants
- 96
- Started
- 2024-07-02
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for diabetic nephropathies
- • Phase2 - 96 participants
- • This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\])
Who can take part?
- • Ages 18 Years to 75 Years
- • Diagnosed with diabetic nephropathies
Where?
- • Derby - Royal Derby Hospital
- • Leicester - College of Life Sciences, University of Leicester
- • London - Barts Health NHS Trust
- • Manchester - Manchester University NHS Foundation Trust
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 75 Years
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Adults, age 18-75 years
- ✓eGFR greater than or equal to 30 mL/min/1.73 m2
Who cannot take part
- ✗Currently pregnant or planning to become pregnant
- ✗History of organ transplantation
- ✗History of alcohol or substance use disorder
- ✗Acute dialysis or acute kidney injury within 6 months of Screening
- ✗Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from...
See the full criteria
Where Is This Study? (5 UK sites)
Royal Derby Hospital
Derby DE22 3NE, United Kingdom
College of Life Sciences, University of Leicester
Leicester LE1 7RH, United Kingdom
Barts Health NHS Trust
London E1 2ES, United Kingdom
Manchester University NHS Foundation Trust
Manchester M13 9WL, United Kingdom
Salford Royal NHS Foundation Trust
Salford M6 8HD, United Kingdom
How to Get in Touch
Michelle Skupien
Sponsor contactCONTACT